miR-342-E2F network drives TNBC metastasis
Analysis based on 6 articles · First reported Aug 21, 2026 · Last updated Sep 09, 2026
The discovery could expand the use of Pfizer's palbociclib into triple-negative breast cancer, a market with high unmet need, potentially increasing drug sales and benefiting Pfizer. It also validates the miR-342-E2F pathway as a therapeutic target, which may spur investment in related diagnostics and therapies.
Australian researchers from the University of Adelaide and the Ludwig Cancer Research identified a molecular mechanism regulating metastasis in triple-negative breast cancer (TNBC). They found that low levels of miR-342 and high activity of the E2F pathway are associated with increased metastatic risk. In pre-clinical models, restoring miR-342 reduced cancer spread, and the existing CDK4/6 inhibitor palbociclib (marketed by Pfizer) significantly reduced metastatic tumor growth in models with low miR-342. The findings, published in EMBO Molecular Medicine on August 21, 2026, suggest that measuring miR-342 levels could identify TNBC patients who might benefit from CDK4/6 inhibitors, potentially repurposing an existing therapy. The research is pre-clinical; further validation and clinical trials are needed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard